|
Platelet function inhibitors
Citations 151-160 of 251 total displayed.
|
Past content
(since Oct 2000):
|
- Editorials
Genetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs
- Andrew I. Schafer
Circulation 2003;108:910-911, doi:10.1161/01.CIR.0000088843.52678.8A
[Full text]
- Articles
Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction. The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
- James E. Tcheng, David E. Kandzari, Cindy L. Grines, David A. Cox, Mark B. Effron, Eulogio Garcia, John J. Griffin, Giulio Guagliumi, Thomas Stuckey, Mark Turco, Martin Fahy, Alexandra J. Lansky, Roxana Mehran, Gregg W. Stone for the CADILLAC Investigators
Circulation published August 25, 2003, doi:10.1161/01.CIR.0000087601.45803.86
[Abstract]
- Editorials
Plaque Rupture, Lysophosphatidic Acid, and Thrombosis
- Arthur A. Spector
Circulation 2003;108:641-643, doi:10.1161/01.CIR.0000082307.85449.1D
[Full text]
- Clinical Investigations and Reports
Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery
- N. Zimmermann, A. Wenk, U. Kim, P. Kienzle, A.-A. Weber, E. Gams, K. Schrör, and T. Hohlfeld
Circulation 2003;108:542-547; published online before print as doi:10.1161/01.CIR.0000081770.51929.5A
[Abstract]
[Full text]
- Articles
Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery
- N. Zimmermann, A. Wenk, U. Kim, P. Kienzle, A. -A. Weber, E. Gams, K. Schrör, and T. Hohlfeld
Circulation published July 21, 2003, doi:10.1161/01.CIR.0000081770.51929.5A
[Abstract]
- Correspondence
Atorvastatin–Clopidogrel Interaction • Response
- Paul T. Martin, Russell Denman, Wei C. Lau, Lucy A. Waskell, Charlene J. Neer, Kevin Horowitz, Amy S. Hopp, Alan R. Tait, Eric R. Bates, Paul B. Watkins, David G.M. Carville, and Kirk E. Guyer
Circulation 2003;107:e223, doi:10.1161/01.CIR.0000077528.26542.DC
[Full text]
- Clinical Investigations and Reports
Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity
- Paul A. Gurbel, Kevin P. Bliden, Bonnie L. Hiatt, and Christopher M. O’Connor
Circulation 2003;107:2908-2913; published online before print as doi:10.1161/01.CIR.0000072771.11429.83
[Abstract]
[Full text]
- Correspondence
Atorvastatin and the Ability of Clopidogrel to Inhibit Platelet Aggregation • Response
- Michael Shechter, Wei C. Lau, Lucy A. Waskell, Charlene J. Neer, Kevin Horowitz, Amy S. Hopp, Alan R. Tait, Eric R. Bates, Paul B. Watkins, David G.M. Carville, and Kirk E. Guyer
Circulation 2003;107:e210, doi:10.1161/01.CIR.0000076180.03211.BD
[Full text]
- Articles
Clopidogrel for Coronary Stenting. Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity
- Paul A. Gurbel, Kevin P. Bliden, Bonnie L. Hiatt, and Christopher M. O'Connor
Circulation published June 9, 2003, doi:10.1161/01.CIR.0000072771.11429.83
[Abstract]
- Clinician Update
Unstable Angina and Non–ST-Elevation Myocardial Infarction: Initial Antithrombotic Therapy and Early Invasive Strategy
- Christopher P. Cannon and Alexander G.G. Turpie
Circulation 2003;107:2640-2645, doi:10.1161/01.CIR.0000072246.69344.2D
[Full text]
|
|
